Research Pages

Adipotide is an investigational peptidomimetic designed to home to white-fat vasculature and trigger apoptosis in adipose blood vessels. It has not been approved for routine clinical use, and the best-known efficacy data come from animal and primate work rather than modern human obesity trials.

AOD-9604 is a synthetic fragment of human growth hormone developed to explore lipolytic and anti-obesity effects without the full endocrine profile of native growth hormone. It remains investigational, and its online reputation often exceeds the strength of the published clinical evidence.

BPC-157 is a synthetic gastric pentadecapeptide widely discussed in soft-tissue healing circles. Its reputation is driven mainly by preclinical literature in tendon, ligament, vascular, and gastrointestinal injury models rather than by robust human clinical trials.

BPC/TB500 (10/10mg) is a combination format that pairs two of the most common recovery-oriented peptides in the gray-market landscape. There are no major direct trials on the proprietary blend itself, so the rationale is inferred from the separate BPC-157 and thymosin-beta-derived literature.

BPC/TB500 (5/5mg) is a lower-dose blend that combines BPC-157 with TB-500 for recovery-oriented protocols. Like other blend products, its scientific rationale depends on the component literatures rather than direct, blend-specific trials.

CJC-1295 / Ipamorelin is a popular growth-hormone-axis protocol that combines a long-acting GHRH analog with a selective ghrelin-receptor agonist. The pairing is intended to support endogenous GH release rather than directly replace growth hormone.

DSIP, or delta sleep-inducing peptide, is one of the older neuropeptides in the sleep-optimization world. It is notable more for scientific curiosity and longstanding debate than for a modern evidence package supporting routine clinical use.

Epithalon is a synthetic tetrapeptide discussed in longevity circles for its proposed effects on telomerase and cellular aging. Its scientific profile is driven mostly by experimental and review literature rather than mainstream clinical adoption.

GHK-Cu is a copper-binding peptide best known for its association with dermal repair, collagen signaling, and skin-health applications. Among aesthetic and regenerative peptides, it has one of the more durable mechanistic reputations.

GHK-Cu / TB500 / BPC-157 is a triple blend that merges a copper peptide with two of the most commonly discussed recovery peptides. The formulation is conceptually aimed at combining dermal remodeling with broader tissue-repair signaling.

Hexarelin is a growth-hormone secretagogue from the GHRP family with a long history in endocrine research. It is generally viewed as a potent GH stimulator with broader interest in cardiometabolic and performance-related physiology.

HGH Frag 176-191 is a growth-hormone fragment discussed for body-fat and lipolysis applications. Its appeal comes from the idea that it may retain some fat-targeting biology of GH while avoiding the broader endocrine profile of full-length growth hormone.

IGF-LR3 is a long-acting analog associated with insulin-like growth factor signaling and discussed in muscle-growth and body-recomposition settings. The scientific discussion is rooted in IGF biology, though direct modern clinical outcome literature specific to LR3 is limited.

Ipamorelin is one of the best-known selective GH secretagogues in the peptide space. It is generally positioned as a ghrelin-receptor agonist with a cleaner and more selective growth-hormone release profile than older GHRPs.

KPV is a tripeptide fragment associated with melanocortin biology and increasingly discussed for inflammation and gut-health applications. Its scientific appeal is driven mainly by anti-inflammatory preclinical work.

LL-37 is a human antimicrobial peptide with a legitimate role in innate immunity and host defense. Unlike many wellness peptides, it originates from a well-recognized biologic function in barrier defense and immunomodulation.

MOTS-C is a mitochondrial-derived peptide that has become one of the most scientifically interesting compounds in metabolic optimization. Its appeal comes from real mitochondrial biology and repeated preclinical signals in insulin sensitivity, exercise adaptation, and metabolic stress.

NAD+ is not a peptide, but it belongs in advanced metabolic and longevity discussions because of its central role in mitochondrial function, redox biology, and cellular stress responses. It is one of the most scientifically serious components in the broader optimization landscape.

Oxytocin is a hypothalamic neuropeptide hormone with well-established roles in bonding, parturition, and social signaling. In optimization circles, it is often oversimplified, but the real literature is far more context-dependent and nuanced.

PT-141, also known as bremelanotide, is one of the few peptides in this database with a modern FDA-approved drug analog and a clear clinical identity. It is best understood through the formal bremelanotide literature in sexual-desire disorders.

Retatrutide is a next-generation obesity drug candidate built around GLP-1, GIP, and glucagon receptor agonism. It is not a fringe peptide; it is a serious late-stage metabolic-development program with one of the strongest obesity trial narratives in the pipeline.

Selank is a synthetic peptide analog linked to anxiolytic and neurobehavioral research. Its scientific profile is stronger in preclinical and regional literature than in broad modern global clinical adoption.

Selank / Semax is a nootropic-style combination designed to pair two of the most discussed neuroactive peptides in this category. The logic is that semax may emphasize neurotrophic and cognitive signaling while selank may emphasize stress and anxiety modulation.

Semaglutide is a GLP-1 receptor agonist with a deep modern evidence base in obesity, diabetes, and cardiometabolic risk. In this knowledge base, it functions as a benchmark for what high-quality human peptide-drug evidence looks like.

Semax is a synthetic neuroactive peptide best known for its association with neuroprotection, neurotrophin signaling, and cognitive-performance research. It occupies a more serious scientific niche than generic nootropic marketing often suggests.

Sermorelin is a classic growth-hormone-releasing hormone analog used to stimulate endogenous GH secretion. It occupies a more traditional endocrine niche than many secretagogues because its mechanism directly mirrors upstream pituitary physiology.

Somatropin is recombinant human growth hormone and represents the benchmark against which GH secretagogues and GH fragments are often compared. It is not speculative peptide wellness medicine; it is a well-defined endocrine therapy with decades of clinical use.

TB-500 is generally discussed as a synthetic fragment or analog related to thymosin beta-4 biology and tissue-repair signaling. Its popularity in recovery circles comes mainly from angiogenesis, cell migration, and repair-related literature rather than from modern human outcomes trials.

Tesamorelin is one of the strongest clinically supported GH-axis agents in this database. Unlike many secretagogue-style peptides, it has a formal therapeutic identity and meaningful human data, especially in visceral-adiposity settings.

Thymosin alpha-1 is an immunomodulatory peptide with a deeper clinical and scientific literature than many peptides grouped into the wellness category. Its strength lies in host-defense and immune-regulation biology rather than in body-composition marketing.

Tirzepatide is a dual GIP/GLP-1 receptor agonist with one of the strongest modern evidence bases in obesity and diabetes medicine. In this database, it serves as a benchmark for what late-generation metabolic peptide therapeutics can achieve in humans.

MK-677, also known as ibutamoren, is an orally active ghrelin receptor agonist developed to stimulate endogenous growth hormone release without direct GH injection. It has real human clinical data, but it is not FDA approved.

PE-22-28 is an experimental neuroactive peptide with very limited literature compared with mainstream neuropsychiatric drugs or even better-known nootropic peptides. Its relevance comes from early antidepressant-style animal work, not mature human data.

Pinealon is a niche neuroactive peptide with limited literature focused on neuronal survival, aging-brain biology, and gene-regulatory effects in experimental settings. It is not part of mainstream neurologic care.

SLU-PP-332 is an early-stage metabolic research compound discussed for effects on mitochondrial activity and energy expenditure. It belongs in translational metabolism conversations, not in established obesity-treatment claims.

SS-31, also known in some development contexts as elamipretide, is a mitochondria-targeted peptide investigated for mitochondrial protection, oxidative-stress reduction, and bioenergetic improvement in tissues such as heart and skeletal muscle.

Tesofensine is an investigational anti-obesity compound studied for appetite suppression and body-weight reduction, with human clinical data showing meaningful weight-loss effects. It is pharmacologically distinct from GLP-1 and dual-incretin therapies.

Thymosin beta-4 is a naturally occurring regenerative peptide studied for wound healing, angiogenesis, cell migration, and tissue repair in multiple preclinical systems. It provides the broader biologic context for many TB-500 discussions.

Melanotan II is an experimental melanocortin agonist studied mainly for increased pigmentation and, in some settings, centrally mediated arousal responses. It is not an approved routine therapy.